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Abstract  
Melusin is a muscle-specific protein which interacts with β1 integrin cytoplasmic domain and acts as 
chaperone protein. Its overexpression induces improved resistance to cardiac overload delaying left 
ventricle dilation and reducing the occurrence of heart failure. Here we investigated possible protective 
effect of melusin overexpression against acute ischemia/reperfusion (I/R) injury with or without 
Postconditioning cardioprotective maneuvers. 
Melusin-transgenic (Mel-TG) mice hearts were subjected to 30 minutes global ischemia followed by 60 
minutes reperfusion. Interestingly, infarct size (IS) was reduced in Mel-TG mice hearts compared to 
wildtype (WT) hearts (40.3±3.5% Mel-TG vs. 59.5±3.8% WT hearts; n= 11 animals/group; P<0.05). The 
melusin protective effect was also demonstrated by measuring LDH release, which was 50% lower in 
Mel-TG compared to WT. Mel-TG hearts had a higher baseline level of AKT, ERK1/2 and GSK3β 
phosphorylation, and displayed increased phospho-kinases level after I/R compared to WT mice. Post-
ischemic Mel-TG hearts displayed also increased levels of the antiapoptotic factor phospho-BAD. 
Importantly pharmacological inhibition of PI3K/AKT (Wortmannin) and ERK1/2 (U0126) pathways 
abrogated the melusin protective effect. Notably, HSP90, a chaperone known to protect heart from I/R 
injury, showed high levels of expression in the heart of Mel-TG mice suggesting a possible collaboration 
of this molecule with AKT/ERK/GSK3β pathways in the melusin-induced protection. Postconditioning, 
known to activate AKT/ERK/GSK3β pathways, significantly reduced IS and LDH release in WT hearts, but 
had no additive protective effects in Mel-TG hearts. These findings implicate melusin as an enhancer of 
AKT and ERK pathways and as a novel player in cardioprotection from I/R injury. 
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Introduction 
In the heart, ischemia followed by reperfusion (ischemia/reperfusion, I/R) induces all form of cell death, 
including apoptosis [39, 63], which can be inhibited by pharmacological and genetic approaches 
resulting in a smaller infarct size [11, 30]. Limitation of myocardial injury after I/R depends on critical 
adaptive responses, some of which involve the heat-shock proteins (HSPs) which acts as molecular 
chaperones [37, 46]. In fact, HSP gene expression is induced by virtually any kind of adaptive stress 
conditioning which reduces the damage of subsequent ischemic insult. The prototype of this 
phenomenon is known as preconditioning (PreC), which provides evidence for adaptive responses to 
stress by enhancing the cell tolerance to subsequent ischemia [7, 42, 58]. PreC can be achieved in the 
heart with a variety of stress responses [2, 19, 28, 43, 45], including hypothermia [53] and 
hyperthermia, which of course induces HSPs [33, 34, 46]. In fact, in PreC two temporary distinct 
protective windows have been described: a first one, which provides protection against myocardial 
infarction within 2–3 h after preconditioning stimuli, and a second window of protection, occurring at 
24–72 h after PreC stimuli, which is characterized by a unique gene expression profile, including HSPs 
induction [7, 47]. The introduction of postconditioning (PostC) as an intervention which can be applied 
at the time of myocardial reperfusion, has redirected the attention to the early phase of reperfusion as a 
target for cardioprotection [40, 48, 50, 66, 71]. Studying the signaling moieties implicated in PostC 
versus PreC revealed a common cardioprotective pathway, including, among others, protein kinases 
such as AKT, ERK1/2 and GSK3β. These kinases are recruited at time of myocardial reperfusion and are 
collectively called “reperfusion injury salvage kinase” (RISK)-pathway, which may also recruit anti-
apoptotic mechanistic pathways, including the phosphorylation of Bcl-2-associated death promoter 
(BAD) [13, 24]. The similarity of pathways between pre and postconditioning is in line with the 
observation that the two protections are not additive [23]. 
A second important cardioprotective element, common to PreC and PostC, is represented by chaperone 
proteins, also known as HSPs [12, 18, 41, 63]. We have previously identified melusin as a new muscle-
specific chaperone protein binding to the cytoplasmic domain of β1 integrin and acting as mechanical 
stretch sensor of the cytoskeleton [8]. Analysis of signaling pathways in transgenic mice indicated that 
melusin overexpression induced increased phosphorylation of AKT, GSK3β and ERK1/2 at basal level and 
after pressure overload [15]. Moreover, AKT and GSK3β were under-phosphorylated in response to 
pressure overload in melusin null mice [8]. 
Therefore, since melusin overexpression enhances the phosphorylation of some RISK pathway 
components in non-ischemic conditions and since melusin has been shown to act as a co-chaperone of 
HSP90 [57], we hypothesized that melusin overexpression can trigger adaptive responses enhancing the 
heart tolerance to I/R challenging. To verify this hypothesis, in the present study, we analyzed the 
myocardial injury in melusin overexpressing and littermate wildtype mice after I/R insult. Moreover, the 
implication of the AKT and ERK1/2 signaling pathways was analyzed. Finally, the possibility of an 
additive protective effect by postconditioning was studied in the Mel-TG model. 
 
Methods 
Animals 
Male FVB non-transgenic (wildtype, WT) and FVB transgenic littermate mice overexpressing melusin 
(Mel-TG) [15] received humane care in compliance with Italian law (DL-116, Jan. 27, 1992) and in 
accordance with the Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, revised 1996). All efforts were made to minimize 
suffering. 
Perfusion technique 
Male WT and transgenic littermate FVB mice (Mel-TG) [15] weighing between 25-35 g (10-15 weeks old) 
were given 500 U heparin and anesthetized with sodium pentothal (50 mg/kg) by intraperitoneal 
injections before being culled by cervical dislocation [55, 56]. Hearts were rapidly excised and perfused 
retrogradely at 80 mmHg by the Langendorff technique with Krebs–Henseleit bicarbonate buffer 
containing (mM) NaCl 118, NaHCO3 25, KCl 4.7, KH2PO4 1.2, MgSO4 1.2, CaCl2 1.25, and Glucose 11. The 
buffer was gassed with 95% O2:5% CO2. The temperature of the perfusion system was maintained at 
37°C. The perfusate flowing out of the heart was collected and measured. Collected coronary effluent 
was used for measurement of lactate dehydrogenase (LDH) release (see below) and the coronary flow 
rate was determined by the amount of perfusate measured in a specific time period.  
At the end of perfusion period, hearts were divided in two parts by a transverse section (perpendicular 
to the long axis); while the apical part (less than 1/3 of ventricular mass) was frozen rapidly in liquid 
nitrogen and stored at -80°C and subsequently used for Western blot analysis, the other part was used 
for infarct size assessment (see below). 
Experimental protocol 
I/R groups (Fig 1) 
Group 1 (WT_I/R, n= 11): in order to have a reference group, hearts were harvested from the WT 
animals and allowed to stabilize for 30-min. After a 30-min stabilization period, hearts were subjected 
to a protocol of I/R, which consisted in 30-min of global no-flow, normothermic ischemia and a period 
of 60-min of reperfusion [4]. 
Group 2 (WT_PostC, n= 12): after the 30-min ischemia, the WT hearts immediately underwent a 
protocol of PostC (i.e., 5 cycles of 10-s reperfusion and ischemia) [49, 51]. 
Group 3 (Mel-TG_I/R, n= 11): hearts were harvested from the transgenic animals (Mel-TG) and, as 
above, were perfused for a 30-min stabilization period, then global normothermic ischemia was applied 
by eliminating flow for 30-min, which was followed by 60-min reperfusion. 
Group 4 (Mel-TG_PostC, n= 12): after the 30-min ischemia, the Mel-TG hearts immediately underwent a 
protocol of PostC (i.e., 5 cycles of 10-s reperfusion and ischemia).  
Group 5 (Mel-TG_I/R+WM; n= 5): these hearts were treated with 0.1 μM of the PI3K inhibitor 
Wortmannin (WM) 5-min before ischemia and during the first 20-min of 60-min reperfusion. 
Group 6 (Mel-TG_I/R+U0126; n= 5): these hearts were treated with 50 μM of the MEK1/2 inhibitor 
U0126 five min before ischemia and during the first 20-min of 60-min reperfusion.  
Groups 7-8 Sham groups (WT_SHAM, n= 3 and Mel-TG_SHAM, n= 3) consisted of hearts which after 
stabilization underwent 90-min buffer-perfusion only. 
The dose of inhibitors WM (0.1 μM, Sigma, St. Louis, MO) and U0126 (50 μM, LC Laboratories, Woburn, 
MA) and the concentration of vehicle (DMSO; Sigma, St. Louis, MO) in which the inhibitors were 
dissolved were based on previous studies of myocardial I/R injury [10, 36, 49, 51, 52, 70]. Nevertheless, 
the two inhibitors were tested in hearts of WT animals (n= 3 for each condition) and the maximal DMSO 
concentration (43µl/100ml) was tested in hearts of both strains (n= 3 for each condition).  
Assessment of myocardial injury 
 Infarct size assessment 
Infarct areas were assessed at the end of the experiments with the nitro-blu-tetrazolium (NBT) 
technique in a blinded fashion, as previously described [51]. In brief, immediately after reperfusion, 
hearts were removed from the perfusion apparatus and, after removing and freezing the apical part 
(see above), the basal part of the ventricles was dissected by transverse sections into two-three slices. 
Following 20-min of incubation at 37°C in 0.1% solution NBT (Sigma-Aldrich, St. Louis, MO, USA) in 
phosphate buffer, unstained necrotic tissue was carefully separated from stained viable tissue by an 
independent observer, who was unaware of the protocols. Since the ischemia was global and since we 
analyzed only the basal part of the ventricles the necrotic mass was expressed as a percentage of the 
analyzed ischemic tissue. 
 Lactate dehydrogenase release 
Besides infarct size, myocardial injury was also assessed by measuring LDH release. The perfusion 
effluent was collected for 5-min immediately before ischemia and for the entire reperfusion period. LDH 
released from the heart was determined by spectrophotometric analysis at 340 nm, using a classic 
procedure [6, 49]. 
 
Western blotting groups  
Frozen samples of the four I/R groups (Groups 1, 3, 5 and 6) and samples from other two 
additional Sham (non-ischemic) groups (Groups 7-8) were used for Western blot analysis. For 
Western blotting, hearts were lysed in Tris-buffered saline with 1% Triton X-100, plus Roche 
complete protease inhibitor cocktail containing (mM) NaF 10, PMSF 1 and Na3VO4 1. Protein 
extracts were clarified with three sequential centrifugations for 20 minutes at 20,000 g, at 4°C 
[55, 56]. Western blot band quantifications were performed with Quantity One software (Bio-
Rad). 
Antibodies against the following proteins were used: AKT (#9271)(1:1000, Cell Signaling), Phospho-AKT 
(#9272)(1:1000, Cell Signaling), GSK3β (#610202)(1:1000, BD Transduction Laboratories), Phospho-
GSK3β (#9336S)(1:1000, Cell Signaling), BAD (#9292)(1:1000, Cell Signaling), Phospho-BAD 
(#5284S)(1:1000, Cell Signaling), HSP90 (#610419)(1:1000, BD Transduction Laboratories), GAPDH 
(MAB374)(1:1000, Millipore[C1]), Phospho-p70 S6 Kinase (#9206)(1:1000, Cell Signaling), p70 S6 Kinase 
α (#sc-230)(1:1000, Santa Cruz Biotechnology), ERK1/2 (#sc-93)(1:1000, Santa Cruz) and Phospho-ERK1/2 
(#9101)(1:1000, Cell Signaling). 
Statistical analysis 
All values are expressed as mean ± SE. Data were analyzed using one-way analysis of variance (ANOVA) 
followed by Bonferroni’s post test. For all analyses, a minimum value of P< 0.05 was considered 
significant. Statistical analyses were performed using GraphPad Prism 4 (GraphPad Software version 
4.0). 
 
Results 
Melusin overexpression protects against myocardial ischemia/reperfusion injury. 
Infarct size, after 60-min of reperfusion increased as the duration of ischemia increased from 25- to 45-
min in both heart of wild type (WT) and of melusin transgenic mice (Mel-TG). A period of 30-min of 
ischemia was determined to be optimal for the comparison of myocardial damage studies. While infarct 
size was 59.5±3.8% of risk area in WT hearts subjected to 30-min ischemia and 60-min reperfusion 
(WT_I/R), it was significantly lower, 40.3±3.5% in Mel-TG hearts subjected to the same protocol (Mel-
TG_I/R) (P< 0.05 vs. WT_I/R group) (Fig. 2A).  
Moreover, total LDH release after 30-min of global ischemia and 60-min of reperfusion was almost 
double in WT compared to Mel-TG hearts (431.6±51.1 mU/mg in the WT_I/R and 177.9±19.5 U/mg ww 
Mel_I/R groups (P< 0.01) (Fig. 2B).  
We assessed whether the protective effect of melusin overexpression can be further modified by 
postconditioning maneuvers. As shown in Fig. 2, while the postconditioning maneuvers reduced 
significantly the infarct size and LDH release in WT hearts (infarct size 37±4% of risk area, P< 0.01 vs. 
WT_I/R group; LDH release 172±24 mU/mg ww; P< 0.01 vs. WT_I/R group), these maneuvers had not 
additive effects on reducing the I/R injury observed in the Mel-TG hearts (infarct size 35±3% of risk area, 
P= not significant (NS) vs. Mel-TG_I/R; LDH release 175±41 mU/mg ww; P=NS vs. Mel-TG_I/R; P< 0.01 vs. 
WT_I/R).  
 
Melusin Protection depends on activation of PI3K/AKT and ERK1/2 pathways 
To asses possible mechanisms involved in the melusin induced protection, major signaling pathways 
known to be regulated by melusin were investigated by Western blot analysis of samples collected from 
the same hearts used to determine cardiac injury and in the two Sham groups described in the Method 
section. As shown in Fig. 3, phosphorylation of ERK1/2 (WT_Sham = 0.350±0.063, Mel-TG_Sham = 
1.825±0.014, P< 0.001; WT_I/R = 0.432±0.168; Mel-TG_I/R = 1.845±0.182 P< 0.001) and AKT (WT_Sham = 
0.457±0.032, Mel-TG_Sham = 2.210±0.034, P< 0.05; WT_I/R = 0.232±0.048; Mel-TG_I/R = 1.59±0.585 
P>0.05) was potentiated in Mel-TG hearts compared to WT both in basal condition and after I/R. In 
addition, GSK3β, a kinase down-stream of AKT, was also more strongly phosphorylated in Mel-TG hearts 
compared to WT both in basal condition and after I/R (WT_Sham = 1.390±0.016, Mel-TG_Sham = 
2.130±0.043, P< 0.05; WT_I/R = 0.395±0.099; Mel-TG_I/R = 1.41±0.383 P< 0.05). Moreover, the pro-
apoptotic BAD protein was significantly more phosphorylated in Mel-TG hearts subjected to I/R 
compared to WT (WT_I/R = 0.825±0.207, Mel-TG_I/R = 1.805±0.192, P< 0.05). 
To demonstrate a causal role of increased AKT and ERK1/2 phosphorylation in melusin dependent 
protection, hearts were treated with the PI3K inhibitor Wortmannin (Mel-TG_I/R+WM) and the he 
MEK1/2 inhibitor U0126 (Mel-TG_I/R+U0126). As shown in Figure 4A, WM treatment resulted in a 
strong inhibition of AKT phosphorylation as well as of the downstream kinase GSK3β. Infarct size of Mel-
TG hearts treated with PI3K inhibitor, was significantly higher (P< 0.01) with respect to the Mel-TG_I/R 
group (Figure 4C) and not significantly different from the WT_I/R group (67.2±3.9% and 66.4±8.3%, 
respectively). Accordingly, in Mel-TG_I/R+WM hearts total LDH release was higher (P< 0.05) with 
respect to Mel-TG_I/R group (Figure 4D) and not significantly different from the WT_I/R group 
(416.5±92.7 U/g ww and 396.3±66.0 U/g ww, respectively).  
Similarly MEK 1/2 inhibitor U0126 strongly blunted the phosphorylation of ERK1/2 as well as of the 
downstream kinase p70S6K (Fig. 4B), abolished the protection in the Mel-TG heart, in fact the infarct 
size and LDH total release were significantly higher with respect to Mel-TG_I/R group (68±4% and 
440±83 U/g ww, respectively, P< 0.001 respect to Mel-TG_I/R) (Fig 4C, D). 
We confirmed in 6 additional WT hearts that the two inhibitors did not exacerbate I/R injury in this strain 
(Infarct size 61±3% and 60±3% and LDH release 446±87 U/g ww and 372±63 U/g ww for WN and U0126, 
respectively; P = NS vs. WT_IR). These data are in agreement with those reported on previous studies of 
myocardial I/R injury [10, 52, 70]. 
Finally, we confirmed in 3 WT hearts that DMSO at the used concentrations had not effect on I/R injury 
(Infarct size 57±2% and LDH 375±30 mU/mg, P = NS vs. WT_I/R) [5, 10]. We also showed in 3 Mel-TG 
hearts that DMSO had no effect on damage (Infarct size 37±1% and LDH 215±25 U/mg ww, P = NS vs. 
Mel_I/R).  
Melusin overexpression induces HSP90 upregulation  
Heat shock proteins are known to protect heart from I/R injury [3, 9, 54, 69]. Given that melusin binds 
to HSP90 and is co-expressed with HSPs [57], we evaluated the expression of HSP90, an ATP-dependent 
chaperone known to have a cardio-protective role in I/R [35]. Interestingly, as shown in Figure 3, 
expression of HSP90 was strongly increased in Mel-TG hearts in basal conditions (WT_Sham = 
0.170±0.034, Mel-TG_Sham = 2.230±0.380, P< 0.01). Moreover, in Mel-TG mice, HSP90 expression 
remained higher after I/R (WT_I/R = 0.350±0.063; Mel-TG_I/R = 1.455±0.380 P> 0.05). 
 
Discussion 
Here we demonstrate, for the first time, that the overexpression of the muscle specific small molecular 
chaperone melusin confers resistance to I/R injury to the heart. Melusin over expression is characterized 
by increased phosphorylation of AKT/ERK/GSK3β kinases and overexpression of HSP90. This phenotype 
represents a protective status relevant for heart tolerance against I/R injury, as shown by the fact that 
the pharmacological inhibition of PI3K/AKT and MEK/ERK pathways blunted the cardioprotection 
observed in melusin transgenic mice. Although the involvement of RISK pathway may be species-specific 
[61], the importance of the PI3K/AKT/ERK pathways in protection from I/R damage has been convincingly 
demonstrated by a number of different laboratories [24, 27, 38, 48, 60]. Here we demonstrated a key 
role of the muscle specific protein melusin to regulate these pathways in the context of ischemia and 
reperfusion. This role is further highlighted by a recent report describing that melusin expression 
increases after a permanent coronary ligation [22] and that this increase improves cardiac remodeling in 
a mouse model of myocardial infarction [65]. 
In our study, due to development of necrosis in late reperfusion (60 min), we could have missed the 
peak of phosphorylation. In fact, in conditioned hearts maximal AKT and ERK1/2 phosphorylation were 
observed at 15 min of reperfusion [26]. Moreover, a role may be also played by the dynamic of 
development of myocardial necrosis and the loss of phospho-AKT and phospho-ERK immunoreactivity, 
and, specifically, by the different way of tissue sampling [14]. Nevertheless, in our Mel-TG model levels 
of AKT and ERK1/2 phosphorylation were higher than WT in non-ischemic conditions (Sham). Such 
higher levels were not reduced after I/R in Mel-TG hearts despite the development of necrosis, thus 
supporting an increased process of phosphorylation in post-ischemic phase in surviving cells of melusin 
transgenic hearts. 
The ability of melusin to sustain both the AKT and ERK1/2 pathways is likely based on its function in 
promoting signalosome complex assembly [20]. Notably, we have previously demonstrated the ability of 
melusin to bind p85 regulatory subunit of PI3Kα [68]. Given that PI3Kα is a key upstream regulator of 
AKT, it can be hypothesized that melusin modulate AKT activation by regulating PI3Kα activity. In 
addition, Melusin also organizes a signalosome complex regulating the ERK1/2 pathway [20]. We have 
shown, in fact, that melusin interacts with c-Raf, MEK1/2 and ERK1/2 MAP Kinases, as well as with their 
scaffold molecule IQGAP-1 [55]. An additional key element also present in the complex is the focal 
adhesion kinase FAK. Biomechanical stress leads to activation of FAK, which in turns triggers the MAPK 
cascade leading to ERK1/2 activation.  
Both the AKT and ERK1/2 pathways impact importantly on cardiomyocyte survival. In fact, AKT, via 
GSK3β, plays an important role in the regulation of the mitochondrial permeability transition pore, thus, 
preventing cardiomyocyte necrosis. At the same time, via BAD phosphorylation it protects cell from 
apoptosis, a major cause of tissue damage in reperfusion injury [1, 17, 21, 39, 71]. In addition ERK 
signaling is well known to promote cell survival in different cell types including cardiomyocytes [44, 55, 
59]. The MEK/ERK cascade: from signaling specificity to diverse functions [64]. Moreover, a positive 
crosstalk of ERK and AKT in promoting cells survival has also been reported [16]. 
An additional component possibly involved in melusin-dependent AKT and ERK activation is the 
chaperone protein HSP90. In fact, melusin, by binding to HSP90 [32, 57], acts as co-chaperone and likely 
directs HSP90 toward the signaling substrates, thus, protecting them from dephosphorylation and 
sustaining their activation state. In this context the up-regulation of HSP90 expression observed in 
melusin transgenic hearts could represent an important and interesting crosstalk between chaperone 
and RISK signaling pathways.  However, the present study was not designed to ascertain this crosstalk, 
which deserves future studies. 
The protective effect against reperfusion injury can also be achieved by postconditioning maneuvers [13, 
23-25, 27, 36, 48-51, 62, 66, 67, 71]. Our results indicated that a PostC protocol, protective in WT hearts, 
does not add any further protection in Mel-TG hearts, thus suggesting that the pathway(s) enhanced by 
melusin is similar to that triggered by PostC.  
Our findings suggest potential therapeutic approaches involving the over-expression of melusin. The 
translation to humans might be obtained either by viral vectors to deliver exogenous melusin genes or by 
pharmacological treatment capable to increase the expression of the endogenous melusin gene in 
patients with an high risk profile for heart ischemia. However, the translation of findings on 
cardioprotection from rodents to humans cannot be taken for granted [29] and analysis in larger 
mammals, such as the pigs, may be necessary to support translational application [31].  
In conclusion, here we present first evidences that melusin overexpression has an important protective 
effect against ischemia/reperfusion injury via its ability to boost RISK pathway signaling and by 
increasing HSP90 chaperone protein expression.  
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Figure Legends 
Fig. 1 Experimental protocols. Timeline of the eight experimental groups. Experimental groups 2 and 4: 
vertical lines represent postconditioning protocol at the beginning of reperfusion. Experimental groups 5 
and 6: Wortmaninn (0.1 μM) and U0126 (50 μM) were used as inhibitors of PI3K and MEK1/2 
respectively. Inhibitors were infused 5 min before and 20 min after ischemia. Arrows indicate the sample 
collection for Western blot analysis. For acronyms see the text. 
 
Fig. 2 Infarct size and LDH release. Panel A: infarct size (IS) expressed as percentage of the ischemic 
tissue (IT) resulted smaller in Mel-TG_I/R compared with WT_I/R mice. Panel B: the increase in LDH 
concentrations during reperfusion was lower in Mel-TG_I/R than in WT_I/R mice. While PostC reduced IS 
and LDH release in WT heart, it did not add any further protection in Mel-TG model. * P< 0.05; ** P< 
0.01. 
 
Fig. 3 Melusin overexpression induces AKT pathway activation and HSP90 upregulation. Panel A: 
Western blot analysis of tissue extracts from hearts subjected to ischemia reperfusion or from control 
hearts. GAPDH was used as loading control. Representative Western blot results are shown. Panel B: 
Densitometric quantification of Western blot bands. * P< 0.05; ** P< 0.01; *** P< 0.001 
 
Fig. 4 Inhibition of either AKT or ERK1/2 phosphorylation blocks protection to ischemia reperfusion 
induced by melusin overexpression. Western blot analysis of phosphorylated AKT (P-AKT), GSK3β (P-
GSK3β) (panel A), and phosphorylated ERK (P-ERK) and p70S6K (P-p70S6K) (panel B) on heart extracts 
from melusin overexpressing mice subjected to ischemia/reperfusion (Mel-TG_I/R) in the presence of 
either PI3K inhibitor Wortmannin (WM) or MEK inhibitor U0126. Wild type hearts subjected to 
ischemia/reperfusion were used for comparative purpose (WT_I/R). The histogram shows the 
densitometric quantification of Western blot bands. Representative Western blot results are shown. 
Panel C: infarct size (IS) expressed as percentage of ischemic tissue (IT) resulted larger in Mel-TG treated 
with Wortmannin or U0126 compared to untreated Mel-TG mice. Panel D: the increase in LDH 
concentrations during reperfusion was higher in Mel-TG_I/R treated with Wortmannin or U0126 
compared to untreated Mel-TG mice. * P< 0.05. 
 
 
 
 
